Qure AI vs Riverain Technologies (2026)
Two thoracic imaging companies with different theories about why findings get missed. Qure detects: chest X-ray reading aids including qXR-LN, cleared as a second reader for lung nodules of 6 to 30 mm, and qCT for chest CT nodule measurement, with a lung nodule management pathway around them. Riverain suppresses the vessels, on the argument that nodules are missed because vasculature hides them rather than because nobody looked, which changes what the radiologist sees rather than adding a list. Those are complementary interventions, and a lung program could justify both. Ask both how they perform on your scanners, because thoracic algorithms are sensitive to acquisition and degrade quietly when they move.
- Nodule detection as a second reader: qXR-LN reported sensitivity of 84.1 percent at 0.18 false positives per image in a standalone study across 40 US sites.
- A path beyond the read: CT nodule measurement and a lung nodule management pathway.
- A stated privacy position: its cloud path receives only images stripped of identifiers, and on premise installation is supported.
- Vessel suppression is a specific technical answer to a specific failure, making nodules visible that vasculature obscures.
- A long established thoracic focus, with products in clinical use across several generations of scanner and protocol change.
- For a lung nodule program, a tool designed around why nodules are missed is different from a general findings detector.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Qure AI and Riverain Technologies are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Qure AI | Riverain Technologies |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2016 | 2000 |
| Headquarters | Mumbai, India | Miamisburg, Ohio, United States |
| Website | qure.ai | riveraintech.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Riverain Technologies
-
EHR / interoperability
Riverain Technologies made its ClearRead chest imaging AI available through RapidAI's Enterprise Platform, delivered over Rapid Edge Cloud and inside the Rapid Navigator Pro radiology workflow.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Qure.ai, founded in 2016 in Mumbai with a US entity in New York, sells radiology AI in more than 105 countries through more than 5,500 sites by its own count. Its products are qXR for chest X-ray (detection, reporting, lung nodules and tuberculosis screening), qER for head CT in stroke and trauma, qCT for chest CT nodules and lung cancer, qMSK for musculoskeletal X-ray, and heart failure detection.
Source: AI Health Index, August 2026
Ohio based company whose ClearRead software applies AI to chest CT and chest radiographs. ClearRead CT produces a vessel suppressed series with nodule detection marks, cleared by the FDA in 2016 (K161201) as an aid to the radiologist for pulmonary nodules on chest CT in an asymptomatic population, and extends to coronary artery calcium scoring (K242188, 2024).
Source: AI Health Index, August 2026
Questions buyers ask
How do Qure AI and Riverain Technologies work with the EHR?
For Qure AI, the qXR page promises zero integration effort and deployment on cloud or on premise, the company says its software works with new and old X-ray systems, and the qXR-Detect summary describes results returned to radiology software or the X-ray console; qXR-LN is cleared for use with any DICOM viewer or PACS.
With Riverain Technologies, the 510(k) summaries describe delivery through the same DICOM network interface that supplies the CT series. The home page displays the names of health systems including the VA, Cleveland Clinic, Duke, Cedars-Sinai, Michigan Medicine and University Hospital Zurich, and reports more than 400 customer locations. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How are Qure AI and Riverain Technologies priced and sold?
In Qure AI's case, the portfolio makes the gap matter. Qure sells chest X-ray, head and chest CT and musculoskeletal products under ten US clearances, plus tuberculosis care cascades and the Aira care delivery platform, and nothing says whether indications are licensed singly, bundled by modality or sold as a platform.
For Riverain Technologies, one route to buy is public: ClearRead CT is listed as an application in the Sectra Amplifier Marketplace, the application store for Sectra's PACS, with its integration and regulatory details and no price or licensing terms. The company's home page gives no licensing basis, whether per site, per study or across a health network. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How do Qure AI and Riverain Technologies handle patient data?
Qure's Security and Regulatory page says data is de-identified before it leaves a covered entity's premises for cloud processing, and that on-premise installations may process identifiable images only on servers the customer owns and operates.
In Riverain Technologies' case, the K161201 summary describes a postprocessing application that generates a secondary series from the lung CT; where that processing runs, what is retained afterward, whether customer studies are used to train or improve the models, and whether any de identification is applied are not stated. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Which settings and specialties do Qure AI and Riverain Technologies cover?
Qure covers chest X-ray, head and chest CT and musculoskeletal X-ray, sold to hospitals, imaging centers, teleradiology services, immigration screening and public health programs in more than 105 countries.
With Riverain Technologies, the nodule detection clearance (K161201) covers chest CT in an asymptomatic population with both lungs in the field of view, supported by a multi reader study, so use on diagnostic chest CT in symptomatic patients falls outside the indication as summarized. Calcium scoring (K242188) and pneumothorax (K213566) are cleared; radiograph nodule detection has no US clearance stated. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Riverain Technologies' record has not yet been reviewed on this site, so its side of this page rests on the build record. Do not compare these on findings counts: suppression changes what the reader sees, while detection lists what the model found.
Qure's nodule figure is published without the number of scans tested, so ask for it. Ask both for performance on your own scanner mix and protocols. Qure publishes no price.